AI assistant
JOHNSON & JOHNSON — Director's Dealing 2021
Feb 11, 2021
29750_dirs_2021-02-10_6df6caa4-9d8b-412b-ace1-6be29b3c0c40.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: JOHNSON & JOHNSON (JNJ)
CIK: 0000200406
Period of Report: 2021-02-08
Reporting Person: Taubert Jennifer L (EVP, WW Chair, Pharmaceuticals)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-08 | Employee Stock Options (Right to Buy) | $164.6200 | A | 82127.0000 | Acquired | 2031-02-08 | Common Stock (82127.0000) | Direct |
| 2021-02-08 | Performance Share Units | $ | A | 11429.0000 | Acquired | Common Stock (11429.0000) | Direct | |
| 2021-02-08 | Restricted Share Units | $ | A | 3739.0000 | Acquired | Common Stock (3739.0000) | Direct |
Footnotes
F1: Awarded under Issuer's Long-Term Incentive Plan.
F2: On February 8, 2021, the Issuer's Compensation & Benefits Committe certified the performance factor applicable to Performance Share Units awarded to the reporting person on February 12, 2018 under the Issuer's Long-Term Incentive Plan. These Performance Share Units represent a contingent right to an equal number of shares of Common Stock or the cash value thereof, subject to the reporting person's continued service to the Issuer through the third anniversary of the initial award date.
F3: Awarded under Issuer's Long-Term Incentive Plan. Each Restricted Share Unit represents a contingent right to receive one share of Common Stock and vests three years after date of grant.